Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Djafarian, A
Looking ahead, the next three to five years will likely see poly-agonist differentiation, oral and non-injectable access expansion, and composition-of-mass outcomes emerge as decisive competitive edgeseach visible in both filing activity and the research frontier [1, 2, 9]
Yet these therapies should be viewed as adjuncts, not replacements for established treatments
Presented at the JSSX/ISSX Meeting, Maui, HI October 2005
Doi: 23
It may overdrive metabolic processes initially
US$ 25.15
US$ 23.76
US$ 22.17
